Patents Assigned to New York Blood Center, Inc.
  • Patent number: 8110719
    Abstract: Genetically engineered conditional knock-out mice having conditional disruption of the Abi1/Hssh3bp1 gene are disclosed along with methods of making and using same.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: February 7, 2012
    Assignee: New York Blood Center, Inc.
    Inventor: Leszek Kotula
  • Publication number: 20110091911
    Abstract: Disclosed herein are antibodies, systems and methods for assessing the risk of hemolysis following a blood transfusion with crossmatch incompatible blood. The disclosure provides a method for determining the relative hemolytic index and therefore the risk of post-transfusion hemolysis for said patient.
    Type: Application
    Filed: October 20, 2010
    Publication date: April 21, 2011
    Applicant: New York Blood Center, Inc.
    Inventor: Gregory R. Halverson
  • Patent number: 7928084
    Abstract: Disclosed are methods and compositions for preventing and treating conditions associated with platelet aggregation, comprising administering a therapeutically effective amount of a composition that modifies the interaction of DNAJC10 with ?IIb?3 in a megakaryocyte, thereby altering the expression of ?IIb?3 on the surface of the megakaryocyte.
    Type: Grant
    Filed: August 19, 2009
    Date of Patent: April 19, 2011
    Assignee: New York Blood Center, Inc.
    Inventors: W. Beau Mitchell, Mahmoud Yazdani Abyaneh, Amanda Chen
  • Publication number: 20100266634
    Abstract: The present invention relates to a method for potentiating a specific immune response to an antigen in a mammal in need thereof. The method comprises administering to the mammal an effective amount of Ov-ASP, or at least one subunit of Ov-ASP, and an antigenic moiety.
    Type: Application
    Filed: February 18, 2010
    Publication date: October 21, 2010
    Applicant: NEW YORK BLOOD CENTER, INC.
    Inventors: Angus J. MacDonald, Sara Lustigman
  • Publication number: 20100130430
    Abstract: Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus in a cell. Also provided are methods of treating a mammal infected with a capsid-containing virus. Further provided are methods of treating a mammal at risk for infection with a capsid-containing virus. Methods of making the above peptides are additionally provided, as are uses of the above peptides and pharmaceutical compositions.
    Type: Application
    Filed: October 2, 2007
    Publication date: May 27, 2010
    Applicant: New York Blood Center, Inc
    Inventors: Asim Kumar Debnath, Hongtao Zhang, Qian Zhao
  • Patent number: 7629443
    Abstract: The present invention provides an isolated antibody capable of binding to the receptor-binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) so as to competitively inhibit the binding of the SARS-CoV to host cells. These mAbs or substances can be used: 1) as passive-immunizing agents for prevention of SARS-CoV infection; 2) as biological reagents for diagnosis of SARS-CoV infection; 3) as immunotherapeutics for early treatment of SARS-CoV infection; and 4) as probes for studying the immunogenicity, antigenicity, structure, and function of the SARS-CoV S protein.
    Type: Grant
    Filed: February 8, 2006
    Date of Patent: December 8, 2009
    Assignee: New York Blood Center, Inc.
    Inventors: Shibo Jiang, Yuxian He
  • Publication number: 20090104612
    Abstract: Disclosed herein are nucleic acid molecules which permit the accurate and direct determination of blood groups based on the presence of certain genes. A method of determining blood groups is also provided.
    Type: Application
    Filed: October 20, 2008
    Publication date: April 23, 2009
    Applicant: New York Blood Center, Inc.
    Inventors: Marion Reid, Asok Chaudhuri
  • Patent number: 7348164
    Abstract: The present invention provides a method to diagnostically detect the variants of a given pathogen, such as HIV, hepatitis C, hepatitis B (HBV), Parvovirus B19, etc., with the use of a single detection probe.
    Type: Grant
    Filed: April 17, 2002
    Date of Patent: March 25, 2008
    Assignee: The New York Blood Center, Inc.
    Inventors: Linda Andrus, Carmen Nicola Nichols
  • Publication number: 20070082035
    Abstract: Methods for maintaining a low vaginal pH, preventing the propagation of toxic shock syndrome toxin 1 production during menstruation, preventing the shedding and dissemination of a herpesvirus and treating herpes lesions comprising administering to a human a formulation comprising a pharmaceutically effective amount of an insoluble micronized form of cellulose acetate phthalate or a cellulose acetate phthalate film or a cellulose acetate phthalate porous sponge. Also a method of treating Candida albicans infection comprising administering to a human female a pharmaceutically effective amount of a composition comprising micronized cellulose acetate phthalate and miconazole nitrate.
    Type: Application
    Filed: October 3, 2006
    Publication date: April 12, 2007
    Applicant: NEW YORK BLOOD CENTER, INC.
    Inventors: Alexander Neurath, Nathan Strick, Yun-Yao Li
  • Patent number: 7169547
    Abstract: A therapeutic product formed from a high concentration of white blood cells having a high degree of cell viability. The white blood cells are sequestered from their normal population presence in whole blood by placing the blood into a container and preventing coagulation of the blood, separating the blood into two components, one of which is extremely rich in white blood cells through the use of a reagent and centrifugation, sequestering the white cell concentration, and freezing the white cells.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: January 30, 2007
    Assignee: New York Blood Center, Inc.
    Inventors: Pablo Rubinstein, Philip Henry Coelho, Cladd E. Stevens
  • Publication number: 20060062866
    Abstract: A complex comprising a starch and an active anti-HIV-1 or anti-HIV-2 ingredient of pomegranate juice that is adsorbed on the starch when the starch is in a water insoluble form. The complex inhibits HIV-1 or HIV-2 infection and blocks the binding of HIV-1 or HIV-2 to the CD4 receptor and the CCR5 and CXCR4 coreceptors. The complex is used in a method of preventing HIV-1 or HIV-2 infection comprising administering to a mucous membrane of a human a pharmaceutically effective anti-HIV-1 or anti-HIV-2 amount of the complex.
    Type: Application
    Filed: September 9, 2005
    Publication date: March 23, 2006
    Applicant: NEW YORK BLOOD CENTER, INC.
    Inventors: Alexander Neurath, Nathan Strick, Yun-Yao Li
  • Publication number: 20050070501
    Abstract: A soft, pliable cellulose acetate phthalate (CAP)—hydroxypropyl cellulose (HPC) composite film is provided which is generated by casting from organic solvent mixtures containing ethanol. The film rapidly reduces the infectivity of several sexually transmitted disease pathogens, including the human immunodeficiency virus (HIV-1), herpesvirus (HSV), non-viral sexually transmitted disease pathogens (such as Neisseria gonorrhoeae, Haemophilus ducreyi, Chlamydia trachomatis and Treponema pallidum) and bacteria associated with bacterial vaginosis (BV). The film is converted into a gel/cream and thus does not have to be removed following application and use. In addition to being a topical microbicide, the film can be employed for the mucosal delivery of pharmaceuticals other than cellulose acetate phthalate.
    Type: Application
    Filed: August 16, 2004
    Publication date: March 31, 2005
    Applicant: NEW YORK BLOOD CENTER, INC.
    Inventors: Alexander Neurath, Nathan Strick, Yun-Yao Li
  • Patent number: 6838240
    Abstract: The present invention provides a method for diagnosing Bloom's syndrome (BS) as well as determining whether a subject is a carrier of a mutated BLM gene. The present invention also provides one or more single-stranded nucleic acid probes and antibodies which may be formulated in kits, and used for diagnosing BS or determining whether a human subject is a carrier of a mutated BLM gene. In addition, the present invention provides a method for treating or preventing the onset of BS in a subject in need of such treatment or prevention, as well as vectors and stem cells useful for such treatment or prevention. The present invention also provides a purified and isolated nucleic acid encoding an enzymatically active BLM protein, a vector comprising this nucleic acid, a cell stably transformed with this vector, as well as a method for producing recombinant, enzymatically active BLM protein. A purified, enzymatically active BLM protein is also provided by the present invention.
    Type: Grant
    Filed: January 2, 2001
    Date of Patent: January 4, 2005
    Assignees: New York Blood Center, Inc., University of Cincinnati
    Inventors: Nathan Ellis, James German, Joanna Groden
  • Patent number: 6727240
    Abstract: A method of preventing HIV-1 or HIV-2 infection by administering to a human a pharmaceutically effective anti-HIV-1 or anti-HIV-2 amount of a tin or silicon protoporphyrin IX or tin or silicon mesoporphyrin IX, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 21, 1994
    Date of Patent: April 27, 2004
    Assignee: New York Blood Center, Inc.
    Inventors: Alexander R. Neurath, Shibo Jiang, Asim Kumar Debnath
  • Patent number: 6723322
    Abstract: The present invention provides a method for inducing angiogenesis in a tissue, by contacting the tissue with an amount of Ov-ASP effective to induce angiogenesis in the tissue. The present invention further provides a method for screening for an anti-Ov-ASP factor, by contacting a factor of interest with Ov-ASP, and assessing the ability of the factor to inhibit angiogenic activity of Ov-ASP. Additionally, the present invention provides a method for inhibiting angiogenesis in a subject.
    Type: Grant
    Filed: April 3, 2000
    Date of Patent: April 20, 2004
    Assignees: New York Blood Center, Inc., Case Western Reservei University, UAB Research Foundation
    Inventors: Sara Lustigman, Eric Pearlman, Thomas R. Unnasch
  • Patent number: 6670123
    Abstract: The present invention provides an isolated nucleic acid encoding KIAA0918, an isolated nucleic acid that hybridizes under high stringency conditions to a nucleic acid that is complementary to a nucleic acid encoding KIAA0918, a purified KIAA0918 protein, a purified protein encoded by a nucleic acid that hybridizes under high stringency conditions to a nucleic acid that is complementary to a nucleic acid encoding KIAA0918, a method of making KIAA0918 protein, an antibody specific for KIAA0918, a method for producing an antibody specific for KIAA0918 protein, a vector comprising a nucleic acid encoding KIAA0918, and a host cell transformed with a vector comprising a nucleic acid encoding KIAA0918. Also provided are methods for detecting the presence of and isolating hematopoietic stem cells in a heterogeneous cell suspension and for assessing gene expression in a tissue sample.
    Type: Grant
    Filed: November 3, 2000
    Date of Patent: December 30, 2003
    Assignee: New York Blood Center, Inc.
    Inventors: Alexander Belyavsky, Sergey Shmelkov, Jan Visser
  • Patent number: 6610501
    Abstract: The present invention provides a porcine antigen that binds to human xenoreactive antibodies. The porcine antigen differs from the known porcine xenoantigens in that the antigen does not include an &agr;Gal epitope. The present invention also provides methods to purify the porcine antigen of the invention, as well as agents that bind to the antigen. The antigen may be used to generate antibodies against the antigen. The antigen is useful for detecting the presence of human xenoreactive antibodies against the antigen in blood and blood compositions, and antibodies against the antigen may be used to detect the presence of the antigen in samples. The invention also provides methods and pharmaceutical compositions for reducing a host rejection response to a porcine xenograft. Finally, a method to treat human blood or blood-derived compositions to reduce the level of human xenoantibodies is disclosed.
    Type: Grant
    Filed: January 2, 2001
    Date of Patent: August 26, 2003
    Assignee: New York Blood Center, Inc.
    Inventor: Alex Zhu
  • Patent number: 6607914
    Abstract: The present invention provides a purified and isolated nucleic acid encoding a camello protein. The present invention also provides a vector comprising nucleic acid encoding camello, a host cell transformed with the vector, and a method for producing recombinant camello protein. In addition, the present invention also provides a purified camello protein. Also provided by the present invention is nucleic acid probes and mixtures thereof specific for camello nucleic acid and antibodies immunoreactive with camello. The present invention also provides a methods for screening for agents which bind to the camello protein and the nucleic acid encoding the camello. Finally, the present invention provides a non-human, transgenic model for camello expression.
    Type: Grant
    Filed: June 14, 2000
    Date of Patent: August 19, 2003
    Assignee: New York Blood Center, Inc.
    Inventors: Alexander V. Belyavsky, Natalia N. Luchinskaya, Anna E. Popsueva
  • Patent number: 6596497
    Abstract: A method for the screening of antiviral compounds targeted to the HIV gp41 core structure comprising capturing polyclonal antibodies from an animal other than a mouse directed against a trimer of a heterodimer containing an N-peptide and a C-peptide onto a solid-phase, mixing a compound to be tested with an N-peptide and then adding a C-peptide, adding the resultant mixture to the resultant polyclonal antibody coated solid-phase and then removing unbound peptides and unbound compound, adding a monoclonal antibody directed against the trimer of a heterodimer containing an N-peptide and a C-peptide and measuring the antibody binding of the monoclonal antibody.
    Type: Grant
    Filed: March 14, 2000
    Date of Patent: July 22, 2003
    Assignee: New York Blood Center, Inc.
    Inventors: Shibo Jiang, Asim K. Debnath
  • Patent number: 6596297
    Abstract: An intravaginal bio-erodible microbicidal barrier device. The device comprises (a) at least one micronized compound selected from the group consisting of cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate, and (b) at least one pectin, such as an apple pectin, and optionally at least one water soluble or water dispersible cellulose compound selected from the group consisting of hydroxypropylmethylcellulose, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose, hydroxyethylethylcellulose and hydroxypropylethylcellulose. The device is prepared by a combination of foaming, freezing and freeze-drying processes.
    Type: Grant
    Filed: March 5, 2002
    Date of Patent: July 22, 2003
    Assignee: New York Blood Center, Inc.
    Inventors: Alexander Robert Neurath, Nathan Strick